Zurcher Kantonalbank Zurich Cantonalbank Has $45.96 Million Stake in Celgene Co. (CELG)

Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in Celgene Co. (NASDAQ:CELG) by 12.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 315,204 shares of the biopharmaceutical company’s stock after selling 42,849 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Celgene were worth $45,963,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Capital Counsel LLC NY lifted its stake in shares of Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC raised its stake in Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 11 shares during the period. Savant Capital LLC raised its stake in Celgene by 0.9% during the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 20 shares during the period. TCI Wealth Advisors Inc. raised its stake in Celgene by 0.9% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 26 shares during the period. Finally, Granite Investment Advisors LLC raised its stake in Celgene by 1.1% during the 2nd quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 29 shares during the period. 79.85% of the stock is currently owned by institutional investors.

Several brokerages recently commented on CELG. Piper Jaffray Companies reaffirmed a “hold” rating and set a $104.00 price objective on shares of Celgene in a research note on Thursday. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 price objective on the stock in a research note on Wednesday. Cantor Fitzgerald set a $112.00 price objective on Celgene and gave the stock a “hold” rating in a research note on Wednesday. Mizuho reaffirmed a “buy” rating and set a $128.00 price objective on shares of Celgene in a research note on Wednesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $147.00 price objective on shares of Celgene in a research note on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $129.98.

Shares of Celgene Co. (CELG) opened at $101.72 on Friday. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The stock has a market capitalization of $80,090.00, a PE ratio of 23.99, a price-to-earnings-growth ratio of 0.65 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 EPS. equities research analysts forecast that Celgene Co. will post 6.7 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://weekherald.com/2018/01/19/zurcher-kantonalbank-zurich-cantonalbank-has-45-96-million-stake-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply